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The Selective Chemo-
radiation in Advanced
Localised Pancreatic Cancer
trial was a randomized,
phase 2 trial in which pa-
tients with locally advanced,
inoperable pancreatic cancer
were given capecitabine- or
gemcitabine-based chemo-
radiation. This paper reports
the health-related quality of
life (HRQL) data, including
validation of the QLQ-
PAN26 tool in chemo-
radiation therapy. Data
support the use of chemo-
radiation as a treatment
option (with capecitabine-
based chemoradiation
preferred) and the use of the
QLQ-PAN26 as a valid tool.Purpose: Chemoradiation therapy (CRT) for patients with locally advanced pancreatic
cancer (LAPC) provides survival benefits but may result in considerable toxicity.
Health-related quality of life (HRQL) measurements during CRT have not been widely
reported. This paper reports HRQL data from the Selective Chemoradiation in
Advanced Localised Pancreatic Cancer (SCALOP) trial, including validation of the
QLQ-PAN26 tool in CRT.
Methods and Materials: Patients with locally advanced, inoperable, nonmetastatic
carcinoma of the pancreas were eligible. Following 12 weeks of induction gemcitabine
plus capecitabine (GEMCAP) chemotherapy, patients with stable and responding dis-
ease were randomized to a further cycle of GEMCAP followed by capecitabine- or
gemcitabine-based CRT. HRQL was assessed with the European Organization for
Research and Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30) and the EORTC Pancreatic Cancer module (PAN26).
Results: A total of 114 patients from 28 UK centers were registered and 74 patients
randomized. There was improvement in the majority of HRQL scales during induction
chemotherapy. Patients with significant deterioration in fatigue, appetite loss, and
gastrointestinal symptoms during CRT recovered within 3 weeks following CRT. Dif-
ferences in changes in HRQL scores between trial arms rarely reached statistical sig-
nificance; however, where they did, they favored capecitabine therapy. PAN26 scales
had good internal consistency and were able to distinguish between subgroups of
patients experiencing toxicity.
Conclusions: Although there is deterioration in HRQL following CRT, this resolves
within 3 weeks. HRQL data support the use of capecitabine- over gemcitabine-
based chemoradiation. The QLQ-PAN26 is a reliable and valid tool for use in patients
receiving CRT.  2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
SCALOP HRQL 811Introduction
Pancreatic cancer patients have a 5-year survival rate of less
than 5% (1). Treatment with chemoradiation therapy (CRT)
may improve overall survival in patients with locally
advanced inoperable tumors but may result in considerable
toxicity (2). Health-related quality of life (HRQL) mea-
surements, not widely reported in the published reports, are
therefore relevant when interpreting trial data and when
making treatment recommendations for patients with
advanced pancreatic cancer.
The Selective Chemoradiation in Advanced Localised
Pancreatic Cancer (SCALOP) trial was a randomized
phase 2 trial that compared gemcitabine-based CRT
(Gem-CRT) and capecitabine-based CRT (Cap-CRT)
following a course of induction chemotherapy in locally
advanced pancreatic cancer (LAPC). The SCALOP trial
demonstrated that Gem-CRT was associated with more
instances of Common Terminology Criteria for Adverse
Events (CTCAE) grade 3 and 4 hematological and non-
hematological toxicities and inferior median survival
(Gem-CRT 13.4 vs Cap-CRT 15.2 months, PZ.012) (3).
In SCALOP, HRQL was assessed with the European
Organization for Research and Treatment of Cancer
(EORTC) QLQ-C30 (4) and the pancreatic cancer module
EORTC QLQ-PAN26 (5). The PAN26 was developed forpatients undergoing surgery, palliative chemotherapy, and
endoscopic treatment of pancreatic cancer, but has not
been previously validated in CRT.
This paper describes generic, disease- and treatment-
specific HRQL during and after treatment with CRT. It also
provides validation and reliability data on QLQ-PAN26 in
patients receiving CRT.
Methods and Materials
Participants and methods
SCALOP was a multicenter, open-label, randomized, par-
allel, 2-arm, phase 2 trial conducted in the United Kingdom
(3). Patients with locally advanced, inoperable non-
metastatic, histologically confirmed carcinoma of the
pancreas were eligible. Registered patients received 3 cy-
cles of gemcitabine and capecitabine (GemCap) chemo-
therapy and were then restaged with CT scans of the thorax,
abdomen, and pelvis. Patients with stable or responding
disease (according to Response Evaluation Criteria In Solid
Tumors criteria, version 1.1), a tumor diameter of 6 cm or
less, and a World Health Organization performance status
0 to 1 were randomized 1:1 to either Gem-CRTor Cap-CRT
by stratified minimization with a random element (80:20).
All participants provided written informed consent. The
Hurt et al. International Journal of Radiation Oncology  Biology  Physics812study was approved by the UK Medical Research and
Ethics Committee and UK Medicines and Healthcare
products Regulatory Agency (MHRA). This study was
registered at International Standard Randomised Controlled
Trial Number (ISRCTN), number 96169987. The full
protocol can be accessed at: http://www.wctu.org.uk/
publications/scalop/SCALOP%20Clinical%20Protocol%
20v4.0.pdf.
Treatment protocol
Induction chemotherapy consisted of 3 cycles of gemcita-
bine (1000 mg/m2 intravenously over 1 hour on days 1, 8,
and 15 of a 28-day cycle) and capecitabine (830 mg/m2
orally, twice daily on days 1 to 21 of a 28-day cycle).
Randomized patients received a further cycle of GemCap
followed by concurrent chemoradiation therapy in combi-
nation with either gemcitabine (300 mg/m2 once per week)
or capecitabine (830 mg/m2 twice daily on days of radiation
therapy only). The total radiation therapy dose was 50.4 Gy
in 28 daily fractions over 5.5 weeks by use of 3-
dimensional conformal or intensity modulated radiation
therapy planning. No subsequent adjuvant therapy was
given.
Health-related quality of life
HRQL was assessed using the HRQL generic instrument,
the EORTC QLQ-C-30, which assesses global quality of
life, functional domains (physical, emotional, social, role,
and cognitive) and symptoms (fatigue, nausea and vomit-
ing, pain, dyspnea, insomnia, appetite loss, constipation,
diarrhea, and financial difficulty) that commonly occur in
patients with cancer (4), and a disease-specific measure, the
EORTC QLQ-PAN26 (pancreatic domain, which uses 26
questions hypothesized as 17 scales and single items spe-
cifically related to pancreatic disease symptoms, treatment
side-effects, and emotional issues) (5). Patients self-
completed paper questionnaires at 6 time points: week
0 (baseline), week 17 (post-induction chemotherapy), week
23 (immediately post-CRT), and subsequently at follow-up
(weeks 26, 39, and 52), even, where possible, if patients
experienced disease progression. Questionnaires were
included if completed within 1 week (4 weeks for weeks 39
and 52) of the specified time point. The EORTC standard
scoring procedure is that function scales and items are
defined such that higher scores represent better HRQL,
whereas symptom scales and items are defined such that
higher scores indicate more symptoms (worse HRQL). The
full list is reported in Table 1.
Data analysis
All randomized patients were included in the analysis.
Analyses were prespecified in the statistical analysis plan
and performed on an intention-to-treat basis (3). Allanalyses were undertaken and graphs produced using Stata
version 13.0 software (Stata Corp., College Station, TX).
Data were imputed according to EORTC guidance if less
than half the items within a scale were missing (6). Where
data were missing from more than half the items within any
scale, these scales were excluded from analyses. When a
complete questionnaire was missing, the reason for the
missing questionnaire was ascertained and categorized.
We performed 2 sets of analyses; 1 set investigated the
change in HRQL during induction chemotherapy (weeks
0 to 17) and the other set analyzed the change from the start
of CRT (week 17) and later time points to assess the specific
impact of CRT on HRQL and difference between arms.
Changes in mean HRQL between earlier and later time
points in all patients were normally distributed (assessed
using Shapiro-Wilk tests for normality) and were presented
with mean scores at each time point, changes in mean
scores, and 95% confidence intervals around those changes.
Changes in scores of 10 or more points were considered
clinically significant (7). When these data were split by
treatment arms to compare changes in HRQL during and
after CRT, the data were no longer normally distributed,
and therefore, Wilcoxon rank sum tests were used to
compare changes between arms. We had no a priori hy-
potheses as to which specific scales would be most affected
by which arm, so we compared all scales and highlighted
results at a P level of <.05 (and a P level of <.01 to reduce
errors from multiple testing) in these exploratory analyses.Psychometric testing of the QLQ-PAN26
Cronbach’s alpha coefficient was calculated as a mea-
surement of reliability of the QLQ-PAN26, using data
from the week-23 assessments. Cronbach’s alpha mea-
sures intercorrelation between the test scores of related
items within the scales, and an alpha value of 0.70 in-
dicates good consistency (8). Construct validity was
assessed by observed differences in the scales at the time
point immediately after CRT (week 23) between the group
of patients who had any CTCAE grade 3 or 4 recorded by
nurses and those who did not. It was hypothesized that
patients with grade 3 or 4 adverse events would report
worse scores in more scales than patients without any
events. Additional known group comparisons were made
in the “side effects scale” between patients with and
without a serious adverse reaction (SAR) persisting at the
week-23 time point, where symptoms are typically most
severe. SARs were defined with at least the possibility of
a causal relationship to one of the trial medications
(including radiation therapy).Role of funding source
The study was funded by Cancer Research UK Clinical
trials Awards and Advisory Committee (CRUK 07/040),
Table 1 QLQ scales, abbreviations, and imputations
Scale Abbreviation QLQ
Items
in scale
Number of
questionnaires with
at least one item of
the scale missing*
Of those,
number imputed
by EORTC
guidelines
Global GQOL C30 2 2 0
Functional
Physical Physical C30 5 5 4
Role Role C30 2 2 0
Emotional Emotional C30 4 4 3
Cognitive Cognitive C30 2 0 0
Social Social C30 2 2 2
Symptoms
Fatigue Fatigue C30 3 4 3
Nausea and vomiting Nausea C30 2 1 1
Pain Pain C30 2 5 5
Dyspnoea Dyspnoea C30 1 2 0
Insomnia Insomnia C30 1 2 0
Appetite loss Appetite C30 1 2 0
Constipation Constipation C30 1 1 0
Diarrhea Diarrhoea C30 1 3 0
Financial difficulties Financial C30 1 2 0
Pancreatic pain Panc Pain PAN26 4 14 8
Bloating Bloating PAN26 1 8 0
Gastrointestinal Gastro PAN26 2 8 1
Taste loss Taste PAN26 1 7 0
Indigestion Indigestion PAN26 1 11 0
Flatulence Flatulence PAN26 1 8 0
Weight Weight PAN26 1 7 0
Weak limbs Weak limbs PAN26 1 7 0
Dry mouth Dry mouth PAN26 1 9 0
Jaundice Jaundice PAN26 2 15 8
Altered bowel habit Bowel PAN26 2 13 6
Poor body image Image PAN26 2 11 3
Side effects of treatment Side effects PAN26 1 21 0
Future health concern Future PAN26 1 9 0
Forward planning limited Planning PAN26 1 9 0
Satisfaction with health care Health care PAN26 2 16 9
Sexual dissatisfaction Sexual PAN26 2 72 14
Abbreviations: C30Z General cancer module; EORTCZ European Organization for Research and Treatment of Cancer; PAN26Z Pancreatic cancer
module; QLQ Z Quality of Life Questionnaire.
* Of the total of 305 questionnaires received from all patients across all time points.
Volume 93  Number 4  2015 SCALOP HRQL 813which had no role in study design, data collection, analysis,
or interpretation or writing of this report.
Results
Between December 24, 2009, and October 25, 2011, 114
patients were registered in the trial from 28 hospitals
across the United Kingdom. All patients were followed
until progression, death, or 12-month follow-up assess-
ment. Seventy-four patients were eligible for randomiza-
tion after 3 cycles of induction chemotherapy; 38 were
allocated to receive Gem-CRT and 36 to receive Cap-CRT
(Fig. 1) (3). HRQL data from patients who failed toproceed to randomization after induction were not
included in this analysis because very few patients
completed the questionnaire after disease progression.Questionnaire compliance and missing data
Questionnaire compliance was good throughout the
study, baseline data being available for 34 (94%) of 36
patients receiving Cap-CRT and 35 (92%) of 38 patients
receiving Gem-CRT (Table 2). Rates at the 39-week
time point were reduced to 71% (Cap-CRT arm) and
66% (Gem-CRT arm). Importantly, fewer questionnaires
were returned in the Gem-CRT arm during later time
Assessed for eligibility (n=216)
Excluded (n=102)
Not meeting inclusion criteria (n=79)
Declined to participate (n=19)
Other reasons (n=4)
Allocated to CAP-CRT (n=36) Allocated to GEM-CRT (n=38)
Randomized (n=74)
Registered (n=114)
Excluded (n=40)
Progressed (n=15)
Clinician choice (intolerance/surgery required 
for complications/weight loss) (n=10)
Patient choice (n=9)
Death (n=5)
Should not have been registered (n=1)
Week 1-16 Induction GEMCAP 
Week 17-23 CAP-CRT Week 17-23 GEM-CRT
Follow-up at week 26, 39, and 52
Fig. 1. Flow diagram. Abbreviations: CAP_CRT Z capecitabine-based chemoradiation therapy (CRT); GEMCAP Z
gemcitabine plus capecitabine; GEM-CRT Z gemcitabine-based CRT.
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Details and reasons for missing questionnaires are
shown in Table 2. Table 3 suggests that those with
missing questionnaires at later time points (particularly
weeks 26 and 39) had worse overall survival than those
who did complete questionnaires. No problems were
reported regarding patients completing the question-
naires, but Table E3 (available online at www.Table 2 Questionnaire compliance and reasons for missing data by
RT þ capecitabine (nZ36)
Baseline
17
weeks
23
weeks
26
weeks
39
weeks
n % n % n % n % n %
Patients still alive 36 36 35 35 34 2
CRFs returned 34 94 31 86 23 66 24 69 24 71 1
Reasons for nonreturn
Admin error 1 3 3 8 3 9 6 17 2 6
Patient declined 0 0 0 0 0 0 0 0 1 3
Patient too
unwell
0 0 2 6 1 3 4 11 4 12
Unknown 1 3 0 0 8 23 1 3 3 9
Abbreviations: CRFs Z Case report forms; RT Z radiation therapy.redjournal.org) suggests that the scale of sexual satis-
faction in the QLQ-PAN26 questionnaire was not
completed as often as other scales. The reason for
nonreturn was missing for more patients at week 23 than
at other weeks. The week-23 assessment involved a
clinic visit that was not part of standard care, and a
number of centers did not return any CRFs for this time
point, so we cannot ascertain for certain the reason fortreatment group
RT þ gemcitabine (nZ38)
52
weeks Baseline
17
weeks
23
weeks
26
weeks
39
weeks
52
weeks
n % n % n % n % n % n % n %
9 38 38 37 36 29 24
9 66 35 92 30 79 26 70 27 75 19 66 13 54
3 10 3 8 3 8 3 8 3 8 2 7 1 4
0 0 0 0 1 3 1 3 0 0 2 7 0 0
7 24 0 0 0 0 1 3 2 6 4 14 8 33
0 0 0 0 4 11 6 16 4 11 2 7 2 8
Table 3 Overall survival at each time point by question-
naire completion
Time point
Patients with
missing questionnaire
Patients with
questionnaire
n
Overall survival
(95% CIs) n
Overall survival
(95% CIs)
Week 17 13 14.6 (11.3-16.3) 61 15.8 (13.9-20.0)
Week 23 25 14.6 (10.3-16.3) 49 16.5 (14.0-21.5)
Week 26 23 12.7 (9.8-15.0) 51 19.1 (14.6-21.5)
Week 39 31 12.7 (9.5-14.0) 43 19.7 (15.7-23.1)
0
10
20
a
Volume 93  Number 4  2015 SCALOP HRQL 815noncompletion, although it is likely to be administration
error.
We received 305 questionnaires from all patients
across all time points. Only 8 of the 32 HRQL scales had
at least 1 missing item in more than 3% of the 305
questionnaires. Of those 8 scales, 7 had at least 1 missing
item in less than 7% of the 305 questionnaires. The other
scale, sexual dissatisfaction, had at least 1 missing item in
24% of the 305 questionnaires. Only those scales with
more than at least half of the items completed could be
imputed using the EORTC method, thus only 1 (sexual
dissatisfaction) of the 32 scales had more than 3% of
values imputed using the EORTC method. Data from the
52-week follow-up were omitted from further analyses
due to the low return rate.–3
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Baseline scores for functional scales were all greater than
64, similar to findings in other studies of pancreatic cancer.20
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Fig. 2. Changes in mean HRQL scores following in-
duction chemotherapy (between week 0 and week 17) with
95% confidence intervals. Negative score indicates deteri-
oration in both function and symptom scales. Abbrevia-
tions: GQOL Z Global Quality of Life Scale; HRQL Z
health-related quality of life.The range of possible scores is 0 to 100; our unpublished
data show median scores for function scales of 90 to 100 in
patients with symptomatic gallstones and in a sample of
normal individuals (C. Johnson, unpublished data). Base-
line scores for all symptom scores were below 50, except
for future health concern (mean: 58.18). For comparison,
patients with symptomatic gallstones score their pain at
approximately 50 and normal individuals at <5 (C. John-
son, unpublished data).
Figure 2 and Table E3 (available online at www
.redjournal.org) show that, for all randomized patients,
the mean changes in the majority of scales show
improvement during induction chemotherapy with clinical
significance achieved in the pain (11.02; 95% confidence
interval [CI]: 18.08 to 3.96), appetite loss (13.56;
95% CI: 23.90 to 3.22), pancreatic pain (14.32; 95%
CI: 21.02 to 7.62), weight loss (10.34; 95% CI:
20.62 to 0.06), and future health (10.30; 95% CI:
18.78 to 1.83) scales. QLQ-PAN26 questions relating to
side effects from treatment indicated significant deteriora-
tion (14.97; 95% CI: 5.38-24.55).C
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Week 17–23
Week 17–23 Week 17–26
Week 17–39
Week 17–26
Week 17–39
b
Fig. 3. Changes in mean HRQL scores following che-
moradiation (week 17 to later time points) with 95% con-
fidence intervals. (a) QLQ-C30. (b) QLQ-PAN26. Negative
score indicates deterioration in both functional and symp-
tom scales.
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Figure 3 and Table E4 (available online at www
.redjournal.org) show the mean changes in scale scores
between week 17 (start of CRT) and later time points of
week 23 (at the end of CRT), week 26 (3 weeks post
CRT), and week 39. Most scales deteriorated between the
start (week 17) and end (week 23) of CRT. There was
clinically significant deterioration including fatigue
(11.70; 95% CI: 5.34-18.07), appetite loss (19.57; 95%
CI: 7.65-31.48), and gastrointestinal symptoms (12.22;
95% CI: 2.83-21.61) and no clinically significant im-
provements over this period. However, there were no
significant differences in mean scores between weeks 17
and 26, suggesting that recovery from the acute effects of
CRT occurs within a 3-week period. At week 39 compared
to week 17, there were clinically significant deteriorations
including pain (10.96; 95% CI: 0.52-21.41) and bloating
(10.81; 95% CI; 0.99-20.63).
HRQL by trial arm
Table E5 (available online at www.redjournal.org) sug-
gests that, due to chance, there were some imbalances in
HRQL scale median scores at week 17 (the point of
randomization) between arms. Thus, changes in score
from week 17 and each subsequent time point were
compared rather than absolute scores at each time point.
Table E5 also shows the difference between trial arms in
terms of change in scale scores between week 17 and later
time points. The median change between week 17 and
later time points was never worse in the Cap-CRT arm
than in the Gem-CRT arm. Results of the Wilcoxon rank
sum tests that compared differences between changes in
score suggest little difference between arms, but where
differences were found, each favored Cap-CRT. Between
weeks 17 and 23, there were differences at the P level
of <.05 between trial arms in the distribution of the
change in the following scores: cognitive functioning
(PZ.036), fatigue (PZ.046), bloating (PZ.035), and dry
mouth (PZ.029). Between weeks 17 and 26, this was
only significant for future health (PZ.033). Between
weeks 17 and 39, this was significant for cognitive
functioning (PZ.011), dry mouth (PZ.001), and body
image (PZ.022). The only significant differences at the P
level of <.01 was in dry mouth between weeks 17 and 39
(PZ.001). Graphs of these selected domains are shown in
Figure 4.
Validation of the QLQ-PAN26 questionnaire during
CRT
Cronbach’s alpha was >.7 for all scales (implying good
internal consistency), except for the jaundice scale
(rZ0.46). The jaundice scale has the following 2questions: “have you had itching?” and “to what extent
was your skin yellow?” The correlation between the scores
for these 2 questions was low (Pearson correlation
coefficient Z 0.37).
Table E6 (available online at www.redjournal.org) shows
the mean scores at week 23 in the group of patients who
had any CTCAE grade 3 and 4 during CRT (primarily
gastrointestinal and constitutional) and those who did not.
Clinically significant differences were seen in 8 scales
(primarily gastrointestinal and constitutional) with worse
scores in the patients with more severe adverse events.
There was a significantly worse mean score at 23 weeks in
the “side effects of treatment” scale, comparing those who
had a SAR during CRT and those who did not: 34.9 (nZ44;
95% CI: 27.0-42.7) versus 50.0 (nZ4; 95% CIs: 18.5 to
118.5), although the confidence intervals are wide due to
the small numbers.Discussion
In the SCALOP trial there was improvement in most of the
HRQL scales during induction chemotherapy. There was
significant decline in a number of HRQL scales during CRT
(fatigue, appetite loss, and gastrointestinal symptoms), but
these recovered by 3 weeks after the end of CRT. We
speculate that the clinically significant deterioration in pain
and bloating scores at week 39 was likely to have been due
to disease progression, either clinical or subclinical; how-
ever, as only 6 patients with documented progression had
HRQL recorded at week 39, this conclusion is conjectural.
The exploratory comparisons of differences in HRQL
scores between trial arms rarely reached statistical signifi-
cance, but where they did, they all favored Cap-CRT,
providing support to our previously published data for the
use of Cap-CRT rather than Gem-CRT.
How does SCALOP compare with other HRQL trials in
LAPC? In the E4201 study, which randomized patients to
single-agent gemcitabine- and gemcitabine-based CRT,
decline in HRQL scores was noted during CRT, which
returned to baseline levels within 9 weeks of completion
of CRT (9). Despite a large difference in grade 4 toxicity
between the arms, there were no statistically significant
differences in median Functional Assessment of Cancer
Therapy Hepatobiliary and Pancreatic subscale (FACT-
Hep) scale score between the treatment arms. This may
have been due to small patient numbers or to separation in
time of the toxicity and HRQL assessment, so that the
toxicity had resolved when HRQL was recorded. Short
et al (10) reported HRQL using QLQ C30 and QLQ
PAN26 questionnaires from a single-arm study, which
included LAPC (nZ41) and postoperative patients
(nZ22) receiving induction gemcitabine followed by
5-fluorouracil (5-FU)-based CRT (10). CRT improved
local symptoms (pain scores and digestive symptoms),
and the authors suggested that patients with local
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Fig. 4. Changes in selected mean HRQL scores by treatment arm with 95% confidence intervals. (a) Cognitive functioning
(high score indicates better QoL). (b) Fatigue (low score indicates better QoL). (c) Bloating (low score indicates better QoL).
(d) Dry mouth (low score indicates better QoL). (e) Body image (low score indicates better QoL). (f) Future health concerns
(low score indicates better QoL).
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Serrano et al (11) reported HRQL outcomes from a single-
arm phase 2 trial of 2 cycles of neoadjuvant gemcitabine-
oxaliplatin-based CRT (30 Gy in 15 fractions concurrent
with first cycle) in patients with borderline resectable and
resectable tumors (nZ71) (11). This study reported a
decline in global HRQL scores but an improvement in
pancreatic pain at the end of neoadjuvant treatment. Long-term outcome in the unresected population was not re-
ported due to low rates of questionnaire return. Contrary
to these studies, SCALOP showed a temporary deterio-
ration in local symptoms following CRT, although im-
provements in local symptoms were seen during induction
chemotherapy.
The comparison of HRQL outcomes between LAPC
patients treated with chemotherapy alone versus those
Hurt et al. International Journal of Radiation Oncology  Biology  Physics818receiving CRT remains an important but unanswered
question. The clinical outcome from the LAP 07 trial,
randomizing patients between chemotherapy alone and
chemotherapy followed by induction chemotherapy, has
been reported in abstract form only (12). That study showed
no additional overall survival benefit for CRT over and
above chemotherapy alone, calling into question the role of
CRT in this disease. No HRQL data were collected in this
trial.
This is the first study to validate the use of QLQ-PAN26
in patients receiving CRT, a treatment that was rarely used
during its development. To our knowledge, the data pre-
sented here provide the most robust validation to date of the
use of the QLQ-PAN26 in patients receiving CRT. Impor-
tantly, a range of scales and items showed deterioration
between the start and end of CRT but with recovery by
3 weeks after the end of CRT. This corresponds well with
expected side effects of CRT and demonstrates the ability
of PAN26 to detect clinically relevant changes. Scales
showed good correlation with nurse-reported adverse
events and treatment-related toxicities. Finally, the scales
also showed good internal consistency with the exception
of the jaundice scale. This is not surprising, as all patients
were free of jaundice during treatment.
Our study has several limitations. Patient numbers in
each arm were relatively small, resulting in wide confi-
dence intervals, and few of the observed differences
achieved statistical significance. Also, comparing arms,
results of the multiple tests conducted increased the prob-
ability of obtaining a P value of less than .05 by chance.
Additionally, HRQL data from registered patients who did
not proceed to randomization were not captured, restricting
the longitudinal trends shown to a cohort of chemotherapy-
selected patients with stable or responding disease and
therefore better overall prognosis. Importantly, question-
naire return rates continued to decline through the study
period, and it is likely those patients who did not respond to
questionnaires during follow-up experienced a different
HRQL profile. This may be a source of bias; however, data
attrition is a significant problem in all studies of pancreatic
cancer, largely due to the nature of the disease and patients’
frequent rapidly declining health. Our data collection rate
compares favorably with those of the E4201 trial and
Serrano et al (11), in which HRQL questionnaire compli-
ance was 40% at 9 months and 25% at 6 months, respec-
tively (11).
Conclusions
Despite these limitations, this study has confirmed the
validity of the QLQ-PAN26 in patients receiving CRT. It
provides detailed insight into HRQL following induction
chemotherapy and consolidation CRT, which has not beenpreviously described. These data will be useful when dis-
cussing therapeutic options in patients with LAPC and lend
further support to the use of capecitabine rather than
gemcitabine as the concomitant cytotoxic in this setting.
Importantly, our data help to dispel any previously held
anxieties and beliefs that CRT is a toxic treatment that will
inevitably detract from HRQL in patients with limited life
expectancy. The role of CRT in this disease remains
controversial, and future trials in LAPC should incorporate
HRQL end points.References
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